Editorial: RAS inhibitor therapy of cancer
- PMID: 40994942
- PMCID: PMC12454064
- DOI: 10.3389/fonc.2025.1685295
Editorial: RAS inhibitor therapy of cancer
Keywords: MAPK inhibitors; RAS; RAS inhibitor therapy; RAS inhibitors; combination therapy with RAS inhibitors and chemotherapy; combination therapy with RAS inhibitors and immunotherapy; combination therapy with RAS inhibitors and other targeted therapies.
Conflict of interest statement
Author GP is co-founder and co-owner of ADT Pharmaceuticals LLC, Orange Beach, AL, USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic RAS inhibitor therapy of cancer
Publication types
LinkOut - more resources
Full Text Sources
